Population pharmacokinetics of methadone in opiate users: Characterization of time-dependent changes

British Journal of Clinical Pharmacology

Volumn 48, Issue 1, 1999, Pages 43-52

  Rostami Hodjegan, Amin ^a,e   Wolff, Kim ^b,f   Hay, Alastair W M ^b   Raistrick, Duncan ^c   Calvert, Robert ^d   Tucker, Geoffrey T ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c Leeds Addiction Unit   (United Kingdom)

^d LEEDS GENERAL INFIRMARY   (United Kingdom)

^e ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Compliance; CYP3A4; Enzyme induction; Methadone; Population kinetics

Indexed keywords

DRUG BINDING PROTEIN; DRUG METABOLIZING ENZYME; METHADONE; OPIATE; OROSOMUCOID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; ENZYME INDUCTION; HUMAN; OPIATE ADDICTION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; FEMALE; HUMANS; MALE; METHADONE; MODELS, BIOLOGICAL; OPIOID-RELATED DISORDERS; TIME FACTORS;

EID: 0033033218     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00974.x     Document Type: Article

References (49)

1. 1 Wolff K, Hay AWM. Plasma methadone monitoring with methadone maintenance treatment. Drug Alcohol Dependence 1994; 36: 69-71.
2. 2 Nilsson MI, Gronbladh L, Wilderlov E, Anggard E. Pharmacokinetics of methadone in methadone maintenance treatment: Characterisation of therapeutic failures. Eur J Clin Pharmacol 1983; 25: 497-501.
3. 3 Loimer N, Schmid R. The use of plasma levels to optimise methadone maintenance treatment. Drug Alcohol Dependence 1992; 30: 241-246.
4. 4 Eap CB, Finkbeiner T, Gastpar M, Scherbaum N, Powell K, Baumann P. Replacement of (R)-methadone by a double dose of (R, S)-methadone in addicts: Inter-individual variability of the (R)/(S) ratios and evidence of adaptive changes in methadone pharmacokinetics. Eur J Clin Pharmacol 1996; 50: 385-389.
5. 5 De Vos JW, Ufkes JGR, Van Brussel GHA, Van Den Brink W. Craving despite extremely high methadone dose. Drug Alcohol Dependence 1996; 40: 181-184.
6. 6 Menelaou A, Dyer KR, White JM, Somogyi AA, Foster DJR, Bochner F. Methadone disposition and plasma concentration-effect relationships in a methadone maintenance program. Proc Austral Soc Exp Pharmacol Toxicol 1995; 2: 112.
7. 7 Wolff K, Hay AWM, Raistrick, Calvert R, Feely M. Measuring compliance in methadone maintenance patients: Use of a pharmacologic indicator to 'estimate' methadone plasma levels. Clin Pharmacol Ther 1991; 50: 199-207.
8. 8 Iribane C, Berthou F, Baird S, et al. Involvement of cytochrome P450 3A4 enzyme in the N-demethylation of methadone in human liver microsomes. Chem Res Toxicol 1996; 9: 365-373.
9. 9 Moody DE, Alburges ME, Parker RJ, Collins JM, Strong JM. The involvement of cytochrome P450 3A4 in the N-demethylation of L-α acetylmethadol (LAAM), norlaam, and methadone. Drug Metab Dispos 1997; 25: 1347-1353.
10. 10 Schall U, Pries E, Katta T, Kloppel A, Gastpar M. Pharmacokmetic and pharmacodynamic interactions in outpatient maintenance therapy of intravenous heroin users with levomethadone. Addiction Biol 1996; 1: 105-113.
11. 11 Nilsson MI, Anggard E, Holmstrand J, Gunne LM. Pharmacokinetics of methadone during maintenance treatment: Adaptive changes during the inductive phase. Eur J Clin Pharmacol 1982; 22: 343-349.
12. 12 Verebely K, Volavka J, Mulé S, Resnick R. Methadone in man: pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther 1975; 18: 180-190.
13. 13 Anggard E, Gunne LM, Holmstrand J, McMahon RE, Sandberg CG, Sullivan HR. Disposition of methadone in methadone maintenance. Clin Pharmacol Ther 1975; 17: 258-266.
14. 14 Wolff K, Rostami-Hodjegan A, Shires S, et al. The pharmacokinetics of methadone in healthy volunteers and opiate users. Br J Clin Pharmacol 1997; 44: 385-392.
15. 15 Leeds Addiction Unit and Northern Regional Drugs and Alcohol Service, Newcastle, Opioid Symptom Severity Assessment (SSA) Chart, 1991.
16. 16 Mentré F, Gomeni G. A two step iterative algorithm for estimation in nonlinear mixed effect models with an evaluation in population pharmacokinetics. J Biopharm Stat 1995, 5: 141-158.
17. 17 Dampster AP, Laird NM, Rubin DB. Maximum likelihood from incomplete data via the EM algorithm. J Roy Stat Soc B 1977; 39: 1-38.
18. 18 Bennet JE, Wakefield JC. A comparison of the Bayesian population method with two other methods as implemented in commercially available software. J Pharmacokinet Biopharm 1996; 24: 403-432.
19. 19 Levy RH, Pitlick WH, Troupin AS, Green JR. Pharmacokinetic interactions of chronic drug treatment in epilepsy: carbamazepine. In The Effects of Disease State on Drug Pharmacokinetics, ed Benet L, Washington DC: Academy of Pharmaceutical Sciences, 1976: 87-95.
20. 20 Meresaar U, Nilsson MI, Holmstrand J, Anggard E. Single dose pharmacokinetics and bioavailability of methadone in man studied with a stable isotope method. Eur J Clin Pharmacol 1981; 20: 473-478.
21. 21 Inturrisi CE, Colburn WA. Pharmacokinetics of methadone. In Advances in Pain Research and Therapy, eds Foley KM, Inturrisi CE, New York: Raven Press, 1986: 191-199.
22. 22 Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criteria (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokin Biopharm 1976; 6: 165-165.
23. 23 Eap CB, Bertschy G, Powell K, Baumann P. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone. J Clin Psychopharmacol 1997; 17: 113-117.
24. 24 Kreek MJ, Garfield JW, Gutjahr CL, Giusti LM. Rifampicin-induced methadone withdrawal. N Engl J Med 1976; 294: 1104-1106.
25. 25 Raistrick D, Hay A, Wolff K. Methadone maintenance and tuberculosis treatment. Br Med J 1996; 313: 925-926.
26. 26 Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47: 1969-1979.
27. 27 Levy RH. Time-dependent pharmacokinetics, In Pharmacokinetics: Theory and Methodology, eds Rowland M, Tucker GT, Oxford: Pergamon Press, 1986: 115-130.
28. 28 Pitlick WH, Levy RH, Troupin AS, Green JR. Pharmacokinetic model to describe self-induced decreases in steady state concentrations of carbamazepine. J Pharm Sci 1976; 65: 462-463.
29. 29 Lai AA, Levy RH, Cutler RE. Time-course of interaction between carbamazepine and clonazepam in normal man. Clin Pharmacol Ther 1978; 24: 316-323.
30. 30 Boddy AV, Cole M, Pearson ADJ, Idle JR. The kinetics of the auto induction of ifosfamide metabolism during continuous infusion. Cancer Chemother Pharmacol 1995; 36: 53-60.
31. 31 Von Bahr C, Steiner E, Koike Y, Gabrielsson J. Time course of enzyme induction in humans: effects of pentobarbital on nortriptyline metabolism. Clin Pharmacol Ther 1998; 64: 18-26.
32. 32 Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: Retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43: 457-466.
33. 33 Ramsay RE, Pellock JM, Garnett WR. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991; 10: 191-200.
34. 34 Abramson FP. Kinetic models of induction: I. Persistence of the inducing substance. J Pharm Sci 1986; 75: 223-228.
35. 35 Scherabaum N, Finkbeiner T, Leifert K, Gastpar LM. The efficacy of 1-methadone and racemic methadone in substitution treatment for opiate addicts-a double-blind comparison. Pharmacopsychiat 1996: 29: 212-215.
36. 36 Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N. Clinical effect and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther 1977; 21: 147-157.
37. 37 Lanz M, Thormann W. Characterisation of the stereoselective metabolism of methadone and its primary metabolite via cyclodextrin capillary electrophoretic determination of their enantiomers. Electrophoresis 1996; 17: 1945-1949.
38. 8]-methadonc. J Pharm Sci 1982; 71: 40-43.
39. 39 Kreek MJ, Hachey DL, Klein PD. Stereoselective disposition of methadone in man. Life Sci 1979; 24: 925-932.
40. 40 Kristensen K, Blemmer T, Angelo HR, et al. Stereoselective pharmacokinetics of methadone in chronic pain patients. Ther Drug Monit 1996; 18: 221-227.
41. 41 Bai SA, Abramson FP. Interactions of phenobarbital with propranolol in the dog: Plasma protein binding. J Clin Pharmacol 1982; 222: 589-594.
42. 1-acid glycoprotein and antipyrine clearance in the dog. Drug Metab Dispos 1986; 14: 46-51.
43. 43 Olsen GD. Methadone binding to human plasma proteins. Clin Pharmacol Ther 1974; 14: 338-343.
44. 1-acid glycoprotein and serum protein binding of methadone in heroin addicts during withdrawal. Proc VI World Congress on Clinical Pharmacogy and Therapeutics, Buenos Aires, Argentina, 1996; 174.
45. 45 Garrido MJ, Jiminez R, Gomez E, Calvo R. Influence of plasma protein binding on the analgesic effect of methadone in rats with spontaneous withdrawal. J Pharm Pharmacol 1996; 48: 281-284.
46. 46 Ball JC, Lange WR, Myers CP, Friedman SR. Reducing the risk of AIDS through methadone maintenance treatment. J Health Soc Behav 1988; 29: 214-226.
47. 1-acid glycoprotein): determinant of free fraction in plasma. Clin Pharmacol Ther 1981; 29: 211-217.
48. 1-acid glycoprotein. Clin Pharmacol Ther 1990; 47: 338-346.
49. 49 Wilkins JN, Ashofteh A, Setoda D, Wheatley WS, Huigen H, Ling W. Ultrafiltration using the amicon MPS-1 for assessing methadone plasma protein binding. Ther Drug Monitor 1997; 19: 83-87.